Evidence map›Paper›PMID 27467934›Full record

ArticleOncoimmunology2016

Notching tumor: Signaling through Notch receptors improves antitumor T cell immunity.

Roman Uzhachenko, Anil Shanker

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Roman UzhachenkoDepartment of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College , Nashville, TN USA.
Anil ShankerDepartment of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, Nashville, TN USA; Host-Tumor Interactions Research Program, Vanderbilt-Ingram Cancer Center, and the Center for Immunobiology, Vanderbilt University, Nashville, TN USA.
Meharry Medical College · US

Funding

Meharry RCMI Program in Women's Health ResearchG12MD007586 · NIMHD · MEHARRY MEDICAL COLLEGE · PI HILDRETH, JAMES E · 2012 to 2016
$7.8M
Role of Fus1-mediated antitumor CD8T-NK crosstalk in Alzheimer's disease pathologySC1CA182843 · NCI · MEHARRY MEDICAL COLLEGE · PI SHANKER, ANIL · 2013 to 2020
$3.1M
Notch ligands in regulation of anti-cancer immunityR01CA175370 · NCI · OHIO STATE UNIVERSITY · PI CARBONE, DAVID P., DIKOV, MIKHAIL M · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA175370NCI NIH HHS SC1 CA182843NIMHD NIH HHS G12 MD007586
6 · The paper itself

Abstract

Notch signaling is crucial for lymphocyte effector and memory differentiation. While tumor suppress Notch signaling in antitumor lymphocytes, recent studies show that the pharmacological Delta-like ligand-1 multivalent cluster or proteasome inhibitor bortezomib can restore Notch-NF-κB signaling in T cells of tumor-bearing hosts with a potential to overcome cancer cell resistance to therapy.

Indexed as

Adoptive T cell therapyantitumor immunitybortezomibcancer immunotherapyDelta-like ligandsimmunosuppressionNotch signaling

Identifiers

PMID27467934
PMCPMC4910711
OpenAlexW2344894768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.